Super selective ophthalmic artery delivery of chemotherapy for intraocular retinoblastoma: 'chemosurgery' the first Stallard lecture

British Journal of Ophthalmology

Volumn 94, Issue 4, 2010, Pages 396-399

  Abramson, David H ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MELPHALAN; TRIETHYLENE MELANAMINE; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CHEMOSURGERY; EDITORIAL; EYE DISEASE; HUMAN; INTRAOCULAR RETINOBLASTOMA; OPHTHALMIC ARTERY; PRIORITY JOURNAL; RETINOBLASTOMA; TREATMENT DURATION; TREATMENT INDICATION;

ANTINEOPLASTIC AGENTS; HUMANS; INFUSIONS, INTRA-ARTERIAL; OPHTHALMIC ARTERY; RETINAL NEOPLASMS; RETINOBLASTOMA;

EID: 77950827265     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2009.174268     Document Type: Editorial

References (27)

1. Balmer A, Munier F, Zografos L. Centenary of the first radiotherapy treatment of retinoblastoma (Hilgartner, 1903) (In French). J Fr Ophtalmol 2003;26:1089-1096.
2. Stallard HB. Comparative value of radium and deep x rays in the treatment of retinoblastoma. Br J Ophthalmol 1952;36:313-324.
3. Reese AB. Retinoblastoma: past, present and future. Bibl Ophthalmol 1968;75:138-141.
4. Sagerman RH, Cassady JR, Tretter P, et al. Radiation induced neoplasia following external beam therapy for children with retinoblastoma. Am J Roentgenol Radium Ther Nucl Med 1969;105:529-535.
5. Wong FL, Boice JD Jr, Abramson DH, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 1997;278:1262-1267.
6. Friend SH, Bernards R, Rogelj S, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 1986;323:643-646 (Pubitemid 16008560)
7. Abramson DH, Melson MR, Dunkel IJ, et al. Third (fourth and fifth) nonocular tumors in survivors of retinoblastoma. Ophthalmology 2001;108:1868-1876.
8. Toral-Martinñon R, Collado-Corona MA, Mora-Magaña I, et al. Evaluation of cisplatin ototoxicity by the audiometric curve in retinoblastoma (In Spanish). Cir Cir 2006;74:79-82.
9. Abramson DH. Retinoblastoma: Diagnosis and management. CA Cancer J Clin 1982;32:130-140.
10. Kim JW, Abramson DH, Dunkel IJ. Current management strategies for intraocular retinoblastoma. Drugs 2007;67:2173-2185 (Pubitemid 47557093)
11. Schefler AC, Abramson DH. Retinoblastoma: what is new in 2007-2008. Curr Opin Ophthalmol 2008;19:526-534.
12. Chan MP, Hungerford JL, Kingston JE, et al. Salvage external beam radiotherapy after failed primary chemotherapy for bilateral retinoblastoma: rate of eye and vision preservation. Br J Ophthalmol 2009;93:891-894.
13. Jehanne M, Lumbroso-Le Rouic L, Savignoni A, et al. Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma. Pediatr Blood Cancer 2009;52:637-643.
14. Wilson M. Abstract ICOO Sept 2009, Cambridge: England.
15. Kupfer C. Retinoblastoma treated with intravenous nitrogen mustard. Am J Ophthalmol 1953;36:1721-1723.
16. Wilson MW, Haik BG, Rodriguez-Galindo C. Socioeconomic impact of modern multidisciplinary management of retinoblastoma. Pediatrics 2006;118:331-336 (Pubitemid 46085374)
17. Jeruss JS, Woodruff TK. Preservation of fertility in patients with cancer. N Engl J Med 2009;360:902-911.
18. Rizzuti AE, Dunkel IJ, Abramson DH. The adverse events of chemotherapy for retinoblastoma: what are they? Do we know? Arch Ophthalmol 2008;126:862-865.
19. Draper GJ, Sanders BM, Kingston JE. Second primary neoplasms in patients with retinoblastoma. Br J Cancer 1986;53:661-671.
20. Schlienger P, Campana F, Vilcoq JR, et al. Nonocular second primary tumors after retinoblastoma: retrospective study of 111 patients treated by electron beam radiotherapy with or without TEM. Am J Clin Oncol 2004;27:411-419 (Pubitemid 39045255)
21. Chaturvedi AK, Engles EA, Gilbert ES, et al. Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst 2007;99:1634-1643.
22. Marees T, Moll AC, Imhof SM, et al. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. J Natl Cancer Inst 2008;100:1771-1779.
23. Felix CA. Secondary leukemias induced by topoisomerase-targeted drugs. Biochim Biophys Acta 1998;1400:233-255.
24. Gombos DS, Hungerford J, Abramson DH, et al. Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor? Ophthalmology 2007;114:1378-1383.
25. Yamane T, Kaneko A, Mohri M. The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma. Int J Clin Oncol 2004;9:69-73. (Pubitemid 38619319)
26. Abramson DH, Frank CM, Dunkel IJ. A phase I/II study of subconjuctival carboplatin for intraocular retinoblastoma. Ophthalmology 1999;106:1947-1950.
27. Brodie SE, Pierre Gobin Y, Dunkel IJ, et al. Persistence of retinal function after selective ophthalmic artery chemotherapy infusion for retinoblastoma. Doc Ophthalmol 2009;119:13-22.